Skip to main content

Table 2 Efficacy of treatment in the XELIRI and FOLFIRI arms (response rate, R0 resection* rate), data are shown as n (%)

From: Capecitabine plus Irinotecan (XELIRI regimen) compared to 5-FU/LV plus Irinotecan (FOLFIRI regimen) as neoadjuvant treatment for patients with unresectable liver-only metastases of metastatic colorectal cancer: a randomised prospective phase II trial

  XELIRI FOLFIRI  
  n = 41 n = 46 p
Complete response 5 (12%) 1 (2%) 0.10
Partial response 15 (37%) 21 (46%) 0.32
Objective response 20 (49%) 22 (48%) 0.76
Stagnation 12 (29%) 10 (22%) 0.67
Progressive disease 7 (17%) 11 (24%) 0.35
R0 resection* 10 (24%) 11 (24%) 0.83
Complete response + R0 resection 15 (37%) 12 (26%) 0.56
  1. R0 resection* – > 10 mm tumour-free resection margin on histology